Do elevated DHEA-S and progesterone suggest increased adrenal steroid activity?

At age 52, concurrent elevations in DHEA-S and progesterone are compatible with increased adrenal steroidogenic activity, but they do not by themselves establish an adrenal disorder or a single cause.

Biological and mechanistic basis

• The adrenal cortex—particularly the zona reticularis—directly produces DHEA-S. CYP11A1 and CYP17A1 generate DHEA from cholesterol-derived precursors; CYB5A supports CYP17A1 17,20-lyase activity, and SULT2A1 uses PAPS to sulfate DHEA into DHEA-S. In human adrenocortical cells, CYB5A silencing reduces DHEA-S output.
• The cortex also produces steroid precursors: CYP11A1 converts cholesterol to pregnenolone, and HSD3B2 converts pregnenolone to progesterone. Thus, progesterone is biologically positioned as an upstream adrenal intermediate rather than necessarily a predominant final adrenal hormone.

Clinical interpretation

• DHEA-S is predominantly adrenal-derived and is a reasonably supported marker of adrenal androgen steroidogenesis. ACTH is the principal acute regulator of adult adrenal C19-steroid production and increases DHEA/DHEA-S secretion. Because DHEA-S clears relatively slowly, it better reflects sustained than acute changes.
• Progesterone can rise with ACTH-driven precursor accumulation, including congenital adrenal hyperplasia (CAH), and with disordered steroidogenesis in adrenal neoplasms. Direct human data show approximately fourfold higher plasma progesterone after ACTH stimulation and an approximately 199-fold increase in adrenal-vein progesterone output measured by LC-MS/MS.

Practical implications

• DHEA-S elevation supports an adrenal contribution; progesterone may reinforce that interpretation in context, but isolated or combined elevations are not source- or diagnosis-specific. In men, circulating progesterone may also be influenced by testicular production, peripheral conversion, medications, and analytical factors.
• Confirmation with LC-MS/MS and assessment of ACTH, morning cortisol, 17-hydroxyprogesterone, androstenedione, and a broader steroid profile can help characterize the pattern. For suspected 21-hydroxylase deficiency, 17-hydroxyprogesterone—not progesterone—is the principal screening marker; cosyntropin testing may be appropriate when suspicion persists.

Bottom line

• Elevated DHEA-S, and potentially progesterone, can reflect increased upstream adrenal pathway activity, but neither result—alone or together—proves generalized adrenal hyperactivity or identifies its cause.